This is the second line opened this year for parenteral drug product clinical and commercial manufacturing, with an annual capacity of 10 million units
This new facility integrates multi-channel chip, micro-mixer system, and complex preparation system into a multi-channel micro-mixer core LNP manufacturing platform
This biopharmaceutical facility is one most significant private sector investment ever in the Middletown region
Site Enhances New Modality CRDMO Platform Capacity for Customers
WuXi STA’s drug product site in Wuxi City offers a full range of services including formulation development and manufacturing for a broad range of oral and injectable dosage forms
Subscribe To Our Newsletter & Stay Updated
_256_275.jpg)